Clinical trial · no report yet · Phase 3
NIAGARA
Durvalumab+ Gemcitabine/Cisplatin (Neoadjuvant Treatment) and Durvalumab (Adjuvant Treatment) in Patients With MIBC
- NCT03732677 ↗
- Active, not recruiting
- AstraZeneca
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| X threads | 2 | |
| Bluesky threads | 1 |
The trial
ClinicalTrials.gov- Official title
- A Phase III, Randomized, Open-Label, Multi-Center, Global Study to Determine the Efficacy and Safety of Durvalumab in Combination With Gemcitabine+Cisplatin for Neoadjuvant Treatment Followed by Durvalumab Alone for Adjuvant Treatment in Patients With Muscle-Invasive Bladder Cancer.
- Phase
- Phase 3
- Status
- Active, not recruiting
- Conditions
- Muscle Invasive Bladder Cancer
- Interventions
- Durvalumab; Cisplatin; Gemcitabine
- Arms
- Arm 1 · Experimental
- Arm 2 · Active comparator
- Enrollment
- 1,063
- Primary outcomes
- Pathologic Complete Response (pCR) Rates at Time of Cystectomy
- Event-free Survival (EFS) Per Central Review Defined as Time From Randomization to Event
- Sponsor
- AstraZeneca
- Start
- Nov 16, 2018
- Primary completion
- Apr 29, 2024
- Results posted
- Yes
- Registry record
- NCT03732677 · updated Oct 15, 2026
Publications
linked from the registry- Powles T, Catto JWF, Galsky MD, Al-Ahmadie H, Meeks JJ, Nishiyama H, Vu TQ, Antonuzzo L, Wiechno P, Atduev V, Kann AG, Kim TH, Suarez C, Chang CH, Roghmann F, Ozguroglu M, Eigl BJ, Oliveira N, Buchler T, Gadot M, Zakharia Y, Armstrong J, Gupta A, Hois S, van der Heijden MS; NIAGARA Investigators. Perioperative Durvalumab with Neoadjuvant Chemotherapy in Operable Bladder Cancer. N Engl J Med. 2024 Nov 14;391(19):1773-1786. doi: 10.1056/NEJMoa2408154. Epub 2024 Sep 15. PubMed 39282910